It is common knowledge that the path to diagnosis for a rare disease sufferer can be long.

There are often devastating emotional and physical consequences. Once diagnosed, things can become a little easier, but the patient and their carer must relentlessly fight to receive the best care. In pharma, orphan drugs are the new frontier. Investment is increasingly flowing in this direction. Offering new hope for countless sufferers. But how can we turn the tide fast enough to increase diagnosis rates and treat more patients?

Download the full article by Samantha Martin - Principal, Incite and Dr Pamela Walker - Director, Incite